N ormal-pressure hydrocephalus, symptoms of which include gait disturbance, urinary incontinence, and dementia, 15 can be successfully treated by shunt surgery, provided that proper patient selection is done. 27, 29 In particular, the use of ELD of CSF to test transient clinical improvement has been important for improving the surgical results. 26, 27, 29 However, our current management of iNPH relies on a limited understanding of the pathophysiological mechanisms behind this condition. 6 Several lines of evidence suggest that metabolic disturbances are involved. 22, 30 In patients with NPH, reduced regional (and global) CBF has been shown. 19, 20, 28, [31] [32] [33] 35, 36, 42 Reduced CBF can be restored by shunt surgery. 28, 32, 36, 42 In a preliminary report of findings in 8 patients, the reduced O 2 metabolism, as assessed by 15 O-PET, was improved by shunt placement. 30 The human data are supported by experimental studies in hydrocephalic animals showing disturbed cerebral metabolism suggestive of chronic cerebral ischemia. 6, 12, 21, 25 Moreover, the alterations in cerebral metabolism can be associated with alterations in ICP. Raising ICP during lumbar infusion testing caused a global reduction in CBF 31 and also impaired periventricular white matter energy metabolism assessed by MD. 2 The change in MD metabolites could be reversed by reducing ICP.
patients with iNPH responding to CSF shunting, which we interpret as reduced intracranial compliance. 7, 10 In this study we monitored cerebral metabolism by using MD and ICP overnight in 40 consecutive patients with iNPH, representing the baseline levels. In a subset of 28 patients, monitoring was continued during a 3-day ELD. The results were related to clinical response to ELD (28 patients) and shunt placement surgery (31 patients). Except for the use of MD in patients with iNPH during lumbar infusion testing, 1,2 results of long-term MD monitoring in iNPH have not been reported previously.
Methods

Patient Population
This investigation was approved by the Regional Ethical Committee for the study of human subjects of the Southeast Health Region in Norway (S-05369) and by the Norwegian Directorate of Health for the establishment of a Research Biobank. Written informed consent was obtained from the patients before their inclusion in the study.
During the study period (April 2006 to January 2008), 40 consecutive patients with clinically evident iNPH, based on symptoms of gait disturbance, incontinence, and dementia combined with ventriculomegaly (Evans index > 0.3; see Eide and Brean 10 ) and confirmed by cranial CT scans were enrolled in a prospective study on cerebral metabolism in which they were monitored by bedside MD and continuous ICP monitoring. Patients were referred to our department from local neurological departments.
Clinical and Radiological Assessment
Patients admitted during the study period were considered surgical candidates and followed a standardized protocol. A general clinical and neurological examination was done at admission. Based on the diagnostic criteria of the recently published classification, 39 our patients with iNPH corresponded to the category "Probable iNPH." The neurological presentation of the severity of symptoms of iNPH was graded according to our NPH Grading Scale (ranging from the highest score [15] to the lowest [3] ), which assesses the severity of gait disturbance (ranging from the highest score [5] to the lowest [1] ), urinary incontinence (ranging from the highest score [5] to the lowest [1] ), and dementia (ranging from the highest score [5] to the lowest [1] ). 7 The patient's history of cerebrovascular comorbidity (transient ischemic attack, narrowing of extracranial cerebral arteries, ischemic stroke), cardiovascular disease (myocardial infarction, valvular disease, cardiac insufficiency, heart arrhythmia, arterial hypertension), and diabetes mellitus was noted.
Admission cerebral CT scans were evaluated for ventricular size by using the linear measures Evans index and ventricular score, 7 and evaluated for absence of cerebral infarction in the area of MD catheter placement.
Monitoring Cerebral Metabolism With MD and ICP
Implantation of the MD and ICP probes was done after local anesthesia was induced in the operating room. A small, straight skin incision and a bur hole ~ 1 cm were made frontally, followed by a small incision in the dura mater. First, an ICP sensor (Codman ICP MicroSensor, Johnson & Johnson) was introduced 2 cm below the cortical surface after being tunneled underneath the scalp and calibrated against atmospheric pressure, as previously described. 7, 10 Then, an MD probe (CMA/71, 20-mm membrane length; CMA Microdialysis) was introduced into the left frontal cortex. Care was taken to avoid insertion of the catheter into brain tissue around the ICP probe. The 20-mm probe then covered a cylinder from the cortical surface to 20 mm below it. The trepanation was closed with tissue glue (Tissell DuoQuick, Baxter AG) to prevent CSF leakage.
The patient was then transferred to the neurosurgical ward, and monitoring was done from the evening to the next day. Twenty-eight of 40 patients were willing to undergo ELD, and in those individuals monitoring was continued during ELD for another 3 days.
During MD monitoring, the probe was perfused with sterile Plasmodex solution at a fixed flow rate of 0.3 µl/ minute by using a microperfusion pump (CMA/106) connected to the inlet tubing. On the outlet tube, perfusates were collected in microvials, which were exchanged hourly and analyzed immediately at bedside in a mobile, photometric, enzyme-kinetic analyzer (CMA/600, CMA Microdialysis) for concentration of lactate, pyruvate, glutamate, and glycerol. To avoid unreliable values due to insertion, the results were accepted after a period of at least 2 hours had passed, which represented a minimum of 3-4 hours after insertion of the MD probe.
We were mindful of the following considerations when assessing whether MD metabolite levels were increased or reduced. Human MD baseline values measured using a 10-mm membrane length at a perfusion rate of 0.3 µl/minute represent ~ 70% of actual values in the interstitial fluid. 17 Baseline MD values obtained from normal frontal cerebral cortex in patients during wakefulness were as follows: lactate 2.9 mmol/L; pyruvate 166 µmol/L; L/P ratio 23; glutamate 16 µmol/L; and glycerol 82 µmol/L. 38 The 20-mm MD membrane and a perfusion rate of 0.3 µl/minute used in our study provides almost 100% recovery; that is, concentrations in the dialysate approach the concentration in the interstitial fluid. Accordingly, we refer to MD metabolites as abnormal based on the following parameters: lactate ≥ 4 mmol/L; pyruvate ≤ 237 µmol/L; L/P ratio ≥ 33; glutamate ≥ 23 µmol/L; and glycerol ≥ 117 µmol/L.
Continuous ICP monitoring was done at 200 Hz, presenting the static (mean ICP) and pulsatile (mean ICP wave amplitude) ICP online (Sensometrics software, dPCom), with an identical time reference as for MD monitoring. Using an automatic algorithm that has been previously described, 8 the cardiac beat-induced singlepressure waves are identified and characterized by their amplitude ("pulse amplitude"), rise time, and rise time coefficient. The parameters "mean ICP" and "mean ICP wave amplitude" were both determined for each consecutive 6-second time window. In our department the criteria for increased intracranial pulsatility are as follows: mean ICP wave amplitude ≥ 4 mm Hg on average, combined with mean ICP wave amplitude ≥ 5 mm Hg in 10% of recording time (a mean ICP wave amplitude of 4-5 mm Hg has been considered borderline). 7, 10 This threshold was used to determine the PPV and NPV for prediction of clinical response to ELD and shunt placement surgery.
Extended Lumbar Drainage
In the 28 patients undergoing ELD, a spinal catheter (Codman Intrathecal Catheter) was introduced at the level of L4/5 and connected to a Codman external drainage set. The device was adjusted to drain ~ 10 ml/hour. The clinical response to ELD was determined by testing gait before and after ELD. The patient was videotaped when standing up, walking a straight distance of 10 m, and then turning 2 times. Improvement (ELD responders) or no improvement (ELD nonresponders) of gait function was determined; no grading of improvement was attempted.
Shunt Placement Surgery
The criteria for surgical treatment were the presence of clinical iNPH, with increased ventricular size (Evans index > 0.3). The results of ICP monitoring were an aid in selecting individuals for surgery, although patients also received surgical treatment when they and their families strongly requested it.
Thirty-one patients underwent surgical treatment with implantation of a ventriculoperitoneal shunt. Two shunt types were used: 27 patients received a HAKIM Programmable Valve Shunt System (Codman & Shurtleff, Inc.), with a median opening pressure at shunt implantation of 12 cm H 2 O (range 10-12 cm H 2 O). The other 4 patients received a programmable gravitational shunt (proGAV shunt system, Aesculap Miethke); the devices were positioned at 5/20 (in 1 patient) and 5/25 (in 3 patients).
Follow-up was done prospectively in our outpatient clinic at 3 months and then at 6-12 months after shunt implantation. The severity of symptoms at follow-up was also graded using our NPH Grading Scale. An increase of ≥ 2 scores on the NPH scale was representative of a significant clinical improvement (shunt responders). The preoperative data were not available at the follow-up reviews.
Statistical Analysis
Statistical analysis was performed using PC-SPSS version 12.0 (SPSS, Inc.). Significance was accepted at the 0.05 level.
Results
Patient Data
Demographic, clinical, and management data in the 40 patients with iNPH are shown in Table 1 . The MD and ICP monitoring caused no complications.
Baseline Levels of MD Metabolites and Static/Pulsatile ICP
The individual baseline values (mean ± SD) of the MD markers and ICP parameters are shown in Table 2 ; baseline levels were derived from a median of 20 hours of MD/ICP monitoring (range 9-43 hours). Increased lactate (≥ 4 mmol/L) was seen in 25 patients (63%), reduced pyruvate (≤ 237 µmol/L) in 24 patients (60%), increased L/P ratio (≥ 33) in 3 patients (8%), increased glutamate (≥ 23 µmol/L) in 15 patients (38%), and increased glycerol (≥ 117 µmol/L) in 2 patients (5%). All 40 patients showed alterations in at least one of the MD metabolite levels. A mean ICP ≥ 10 mm Hg was seen in only 3 (8%) of 40 patients, whereas a mean ICP wave amplitude ≥ 4 mm Hg (and ≥ 5 mm Hg in 10% of recording time) was seen in 24 (60%) of 40 patients.
The baseline levels of MD metabolites were neither significantly correlated with age, duration of symptoms, NPH score (that is, severity of NPH symptoms), nor with Evans index (p > 0.07) or ventricular score (p > 0.12). The pulsatile ICP (mean ICP wave amplitude) was significantly correlated with NPH score (Spearman correlation −0.47; p = 0.002), although it was not correlated with age, duration of symptoms, or ventricular size (Evans index or ventricular score). Hence, a more severe clinical state of NPH (that is, low NPH score) was correlated with increasing pulsatile ICP. This was not seen for static ICP (mean ICP).
At the group level, we found no significant correlations between baseline MD metabolites and pulsatile ICP (mean ICP wave amplitude), or between baseline MD metabolite levels and static ICP (mean ICP; p > 0.1). Table 1 indicates that 73% of patients presented with vascular comorbidity. The baseline levels of MD metabolites were not different between those with or without vascular comorbidity. The pulsatile ICP (the ICP wave amplitude) was significantly higher in those with vascular comorbidity (p = 0.04); this was not seen for static ICP.
Results of ELD
The ELD procedure caused no complications. Among the 28 patients undergoing ELD, 18 were categorized as responders and 10 were nonresponders (Table 1) .
Among the 28 individual patients, during ELD the lactate levels became significantly reduced in 8 (29%), the L/P ratio was significantly reduced in 12 (43%), glutamate was significantly reduced in 21 (75%), glycerol was significantly reduced in 18 (64%), and pyruvate was significantly increased in 23 (82%; data not shown). The ICP wave amplitudes became significantly reduced in all 28 patients, whereas the mean ICP fell significantly in 21 (75%; data not shown). Moreover, significant correlations between MD metabolites and pulsatile ICP were more frequently seen in ELD responders than in nonresponders. The volume drained during ELD did not significantly correlate with the change in MD metabolites or ICP (pulsatile or static) during ELD.
The differences in MD metabolites and ICP parameters before and during ELD for all 28 patients who received this treatment are presented in Table 3 . During ELD, the lactate, pyruvate, and L/P ratio were significantly increased, whereas glutamate, glycerol, and the parameters mean ICP and mean ICP wave amplitude were significantly reduced. The trends in changes before and during ELD for patients who received this treatment are illustrated for glutamate (Fig. 1a), glycerol (Fig. 1b) , lactate (Fig. 1c), pyruvate (Fig. 1d) , and L/P ratio (Fig.  1e) , and for the parameters mean ICP (Fig. 2a) and ICP wave amplitude (Fig. 2b) . The changes in the MD markers lactate, pyruvate, L/P ratio, glutamate, and glycerol during ELD were not significantly correlated with either the changes in static (mean ICP) or pulsatile ICP (the ICP wave amplitude) (p > 0.4).
Importantly, the baseline MD metabolite levels were not significantly different between the ELD responders and nonresponders (Table 4 ). The changes in levels of MD markers during ELD also did not differ between ELD responders and nonresponders (Table 5) .
Whereas static ICP (mean ICP) did not differentiate ELD responders from nonresponders, the ICP wave amplitude was significantly higher in ELD responders than in nonresponders (Table 4) . Moreover, the change in pulsatile ICP from baseline during ELD was more significant in ELD responders than in nonresponders ( Table  5 ). This latter observation is further revealed in Fig. 2c . Taken together, among 15 patients with elevated pulsatile ICP (an ICP wave amplitude ≥ 4 mm Hg on average and . Comparing the data before ELD with those obtained during ELD showed a significant reduction in glutamate (p < 0.001) and glycerol (p < 0.001), and a significant increase in pyruvate (p < 0.001), but also a significant increase in lactate (p < 0.001) and L/P ratio (p < 0.001; Wilcoxon signedrank test).
≥ 5 mm Hg in 10% of recording time), all had a clinical response to ELD, whereas among 13 patients with low pulsatile ICP, only 3 were ELD responders (PPV 100 and NPV 77 for clinical response to ELD).
Results of Shunt Surgery
Among the 31 patients receiving shunts, there were 24 responders and 7 nonresponders (Table 1) ; those classified as shunt responders presented with an increase of ≥ 2 scores on the NPH scale. Shunt surgery caused complications in 5 (16%) of 31 patients, as follows: shunt infection in 3 (10%); chronic subdural hematoma in 1 (3%); and abdominal pain requiring replacement of distal drainage in 1 (3%).
The baseline levels of MD markers did not differ between shunt responders and nonresponders (Table 6 ). The pulsatile ICP (the mean ICP wave amplitude) was significantly higher in shunt responders, which was not seen for static ICP (mean ICP; Table 6 ).
Among the subgroup of 21 patients undergoing both ELD and shunt surgery, we explored how observations during ELD related to clinical response to CSF shunting. The changes in MD metabolites during ELD were not correlated with changes in NPH scores after shunt treatment (total scores or individual gait, urinary incontinence, or memory subscores; Spearman correlations < 0.2; p > 0.10). On the other hand, the reduction in ICP wave amplitude during ELD was highly related to the changes in NPH scores after shunt treatment: the change in NPH score (Spearman correlation −0.6; p < 0.001); change in gait subscore (Spearman correlation −0.7; p < 0.001); change in incontinence subscore (Spearman correlation −0.5; p = 0.005); and memory subscore (Spearman correlation −0.5; p = 0.009). No comparable correlation between change in static ICP (mean ICP) during ELD and change in NPH scores after shunt placement was seen (p > 0.1).
Among the 31 patients treated with shunts, a response was seen in 23 of 24 patients with increased pulsatile ICP (average of ICP wave amplitude ≥ 4 mm Hg and ≥ 5 mm Hg in 10% of recording time), 7 whereas a shunt response was seen in only 1 of 7 patients with low pulsatile ICP (PPV 96, NPV 86).
Discussion
Patient Cohort
Our cohort included patients in whom iNPH was diagnosed based on clinical and radiological findings; these patients' diagnosis corresponded to probable iNPH according to a more recently published classification.
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Our NPH Grading Scale, which was used to determine the severity of their symptoms, 7 compares with an NPH Grading Scale that recently was validated, showing high reliability and validity. 24 
Monitoring of Baseline Levels of MD Metabolites and Pulsatile/Static ICP
In this study, for the first time we report baseline values of MD metabolites during long-term overnight monitoring in patients with iNPH. Baseline values of MD markers in normal human brain during wakefulness were previously reported by Reinstrup et al. 38 Pyruvate is a marker of aerobic energy metabolism and its concentration falls while the lactate concentration rises during ischemia. Lactate alone is a less useful marker of the redox state of the cells because an increase in lactate may be caused by hypoxia and/or ischemia as well as hypermetabolism. 37 The L/P ratio is a well-known marker of changes in the redox state of cells and is a more valuable marker of ischemia than lactate alone. 37 Other studies have suggested that lactate and glutamate can be the most sensitive markers of ischemia, followed by the increased L/P ratio and glycerol values during manifest ischemia and cell degeneration. 34, 41 Both glutamate and glycerol are indicators of cell damage. Thus, increased lactate, L/P ratio, glutamate, and glycerol, and reduced pyruvate may all be associated with anaerobic metabolism. 3, 16, 44 The alterations in MD markers seen in our 40 patients with iNPH at baseline ( Table 2 ) may be indicative of low-grade cerebral ischemia. This observation may support the experimental studies in animals, in which it was found that chronic hydrocephalus can be considered a chronic ischemic condition. 5, 21, 25 A recognized disadvantage with the MD technique is that it provides focal metabolic information, that is, alterations in the area near the MD probe. The location of MD catheters in this series was from the cortical surface to 20 mm below it. Hence, the volume of the tissue sampled by the MD catheter was a cylinder approximately the length of the 20-mm catheter, with a diameter of a few millimeters. Other MD studies in patients with iNPH have placed the MD catheter in the periventricular white matter, which is probably more prone to damage in communicating hydrocephalus.
2 Using PET studies, Momjian et al. 31 showed that CBF at baseline was most reduced in the peri-and paraventricular white matter, with a progressive normalization of CBF with distance from the ventricles. Hence, placement of the MD catheter in periventricular white matter might have shown more pronounced ischemia than presented here. Other investigators have reported no consistent differences in the neurochemistry whether the catheter was placed in white or gray matter, although it is to be expected that the levels of neurotransmitters will vary depending on the position. 44 The matter of interest in patients with iNPH, however, is global ischemia, which should be detected independent of catheter placement.
Another study in which the MD technique was used also indicated an increased baseline L/P ratio within the periventricular white matter of patients with iNPH. 1 Increase in ICP during lumbar infusion testing caused a drop in glucose, lactate, and pyruvate, but no change in L/P ratio or in glutamate; the impaired metabolism was reversed by a subsequent drop in ICP. 2 Hence, there was an immediate and reversible change in energy metabolism but no signs of ischemia. These authors explored the sudden changes in MD metabolites following a rapid alteration in ICP. An advantage with our study is that we developed our baseline measures according to several hours of MD assessment (median 20 hours, range 9-43 hours). Moreover, we started MD monitoring ~ 3-4 hours after insertion of the MD probe and ~ 2 hours after starting the infusion.
There is a well-established association between iNPH and vascular comorbidities such as hypertension, ischemic heart disease, and diabetes. 4, 14, 23, 29, 43 Several authors have stressed that the presence of vascular comorbidity does not impair the results of shunt surgery in iNPH. 18, 19, 43 The present data extend this existing literature by showing that MD metabolite levels were not different between patients with and without vascular comorbidity. However, the pulsatile ICP was significantly elevated in those with vascular comorbidity. 
Results of MD/ICP Monitoring and Clinical Response to ELD
Our observations indicate that ELD improves cerebral metabolism. Among our 28 patients undergoing ELD, a significant reduction was seen for lactate in 29%, L/P ratio in 43%, glutamate in 75%, and glycerol in 64%, whereas pyruvate significantly increased in 82% of the patients. All 28 patients had significant improvement in at least one of the MD metabolites during ELD. At the group level, we found significant improvement during ELD of pyruvate, glutamate, and glycerol, whereas lactate and L/P ratio were significantly increased (Table 3) .
In another study, CSF diversion of a smaller volume (~ 40 ml) increased dialysate concentrations of lactate and pyruvate without changing L/P ratio and glutamate concentrations, which was interpreted as indicative of increased metabolic rate.
1 This is in agreement with our observations. Thus, the increased lactate during ELD probably reflects hypermetabolism. In previous studies, a rather consistent finding is improved CBF after shunt surgery. 20, 28, 32, 33, 42 Also, O 2 metabolism was improved by shunt surgery. 30 Thus, our observations support a view that the alterations in CBF and O 2 metabolism after shunt placement relate to an improvement of chronic ischemia in the brain tissue.
Among our 28 patients undergoing ELD, a significant correlation between pulsatile ICP and the various MD metabolites was more common among ELD responders than in nonresponders. This may indicate that pulsatile ICP relates to cerebral metabolism. In line with this suggestion, others have previously reported an association between higher L/P ratio and reduced intracranial compliance, measured using the Spiegelberg monitor, 40 in patients with traumatic brain injury in whom temperatures are high. On the other hand, at the group level, changes in MD markers during ELD were not related to changes in pulsatile ICP. Moreover, we found no differences in baseline levels of MD metabolites between ELD responders and nonresponders (Table 4 ). The change in MD metabolites during ELD also did not differ between ELD responders and nonresponders (Table 5 ). The only variable that differed between these 2 groups was the pulsatile ICP (mean ICP wave amplitude). The baseline level of ICP wave amplitude was elevated in ELD responders, and the change in ICP wave amplitude during ELD differed significantly between ELD responders and nonresponders.
Taken together, the pulsatile ICP was the only variable differentiating between ELD responders and nonresponders. Even though MD marker levels did not differentiate responders from nonresponders, ELD significantly improved cerebral metabolism. A drawback with our study is that only 28 of 40 patients underwent ELD.
Results of MD/ICP Monitoring Versus Clinical Response to Shunt Surgery
In our rather small cohort of 31 shunt-treated patients, 24 (77%) were responders, whereas 7 (23%) were nonresponders at follow-up review 6-12 months after surgery. This cohort is too small to draw conclusions about shunt response in iNPH, but the results compare with recently published series. McGirt et al. 29 (using 3 days of ELD and a positive finding of A-or B-waves on spinal puncture) found a long-term shunt response rate of 75% in 132 patients. Marmarou et al. 27 also used gait improvement after 3 days of ELD as a factor, and reported clinical improvement in 76 (91%) of 84 patients. Thus, several authorities consider ELD as the "gold standard" in the preoperative diagnostic assessment of iNPH. 26, 27, 29 Others have previously questioned its usefulness, particularly due to its low specificity and complication rate. 45 Although alterations in MD metabolites were common in our patients, the baseline levels of MD metabolites were not different between shunt responders and nonresponders (Table 6 ). Moreover, in the subgroup of patients receiving shunts and also undergoing ELD, the change in MD markers during ELD failed to correlate with clinical response to CSF shunting. On the other hand, this material clearly showed that elevated pulsatile ICP is consistent in shunt responders, which compares with previous findings in our department. 7, 10 Thus, in this cohort of 31 shunt-treated patients, raised pulsatile ICP (that is, mean ICP wave amplitude ≥ 4 mm Hg on average and ≥ 5 mm Hg in 10% of recording time) had very high predictive values for shunt response (PPV 96, NPV 86).
Our interpretation of the finding of increased pulsatile ICP in patients with iNPH responding to CSF shunting is that these patients have reduced intracranial compliance (that is, reduced pressure-volume reserve capacity). In patients with intracranial hemorrhages, we previously reported that intracranial compliance, determined by the Spiegelberg monitor, became reduced when the mean ICP wave amplitude was increased, even though static ICP (mean ICP) was normal.
11 Experimental studies showed that intracranial pulse-pressure amplitudes increase when intracranial compliance is being reduced. 13 It is possible that the increased MD levels seen at baseline in our patients with iNPH are associated with reduced intracranial compliance.
Conclusions
The results of MD monitoring presented in this study provide evidence of low-grade ischemia in patients with iNPH. During ELD, cerebral metabolism is being improved. Thus, the clinical improvement seen following ELD can involve improvement of the biochemical milieu of the nerve cells. However, the levels of MD markers did not differentiate between the ELD responders/nonresponders or shunt responders/nonresponders, and therefore this method is less useful for predicting the outcome of shunt surgery in patients with iNPH. Only the pulsatile ICP differentiated ELD and shunt responders from nonresponders, which supports previous observations. Our interpretation is that elevated pulsatile ICP indicates reduced intracranial compliance. This is improved by CSF diversion, causing improvement of the biophysical milieu of the nerve cells.
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